The move takes place one day after the country’s national drug regulator Anvisa approved the administration of CoronaVac in children and adolescents aged six through 17.
The decision was unanimous. In all, five directors voted for the authorization.The dose was banned for immunosuppressed children and adolescents.
The request concerns test capable of differentiating between Influenza A, B, and Sars-CoV-2, making the diagnosis of these illnesses possible with a single test.
According to a bulletin released by the Ministry of Health, 204,854 cases have been registered in the last 24 hours.The number of people infected totals 23,416,748.
To Brazil’s national drug regulator Anvisa, no studies available are said to demonstrate efficiency
Português 
Español 
